[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360126-105":59,"doc-detail-360126-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","co-delivery-of-cisplatin-and-bmi1-sirna-via-nanocapsules-overcomes-chemoresistance-in-ovarian-cancer","Co-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomes chemoresistance in ovarian cancer","","Ovarian cancer remains highly lethal due to chemotherapy resistance and tumor recurrence. Cancer stem cells contribute to relapse by sustaining self-renewal and enabling survival under cisplatin stress. This study engineered a lipid-coated calcium carbonate nanocapsule system for co-delivery of cisplatin and Bmi1 siRNA, targeting the Bmi1 regulatory axis linked to poor prognosis. In resistant cell models, the formulation improved cisplatin sensitivity; in xenograft and primary ovarian cancer mouse models it suppressed tumor growth without notable systemic toxicity. Tumor analyses showed reduced cancer-stem-cell and multidrug-resistance markers, supporting targeted codelivery nanotherapeutics as a promising strategy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/co-delivery-of-cisplatin-and-bmi1-sirna-via-nanocapsules-overcomes-chemoresistance-in-ovarian-cancer/360126/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/co-delivery-of-cisplatin-and-bmi1-sirna-via-nanocapsules-overcomes-chemoresistance-in-ovarian-cancer/360126.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cisplatin resistance a major issue in ovarian cancer?","Question",{"text":112,"@type":113},"Most patients initially respond to cisplatin but later relapse as resistance develops. This resistance is closely linked to persistent cancer stem cells that survive conventional chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does Bmi1 play in cancer stem cell–mediated chemoresistance?",{"text":117,"@type":113},"Bmi1 supports cancer stem cell self-renewal and survival by regulating pathways such as the Ink4a/Arf locus and other mechanisms affecting apoptosis and DNA repair. Its overexpression correlates with aggressive behavior and poor prognosis.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the CCL@Bmi1 siRNA nanocapsule system work in the study?",{"text":121,"@type":113},"The authors engineered a lipid-coated calcium carbonate nanocapsule system to co-deliver cisplatin and Bmi1 siRNA. This approach increases cisplatin sensitivity in resistant ovarian cancer cells and suppresses tumor growth in mouse models while reducing CSC-associated and multidrug-resistance markers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360126,1790283331,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCo-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomeschemoresistance in ovarian cancer  \nMengbin Liu1, Xing Liu2, Junru Heng1, Changping Li1, Yunlong Duan1, Qi Fu1, Jun Shen1, Binbin Zhang1, Shaohua Zhang3 & Yingying Xie1􀀍  \nOvarian cancer (OC) is a leading cause of gynecological cancer mortality, primarily due to chemotherapy resistance and tumor recurrence. Cancer stem cells (CSCs), regulated by key factors like Bmi1, play a pivotal role in this resistance by maintaining CSC self-renewal and promoting tumor progression. However, effective treatments targeting these mechanisms remain limited. We engineered a lipid-coated calcium carbonate-based nanocapsule system (CCL) for co-delivery ofcisplatin and Bmi1 siRNA (CCL@Bmi1 siRNA) to overcome cisplatin resistance in OC. Bioinformatics analysis revealed significant upregulation of Bmi1 in OC tissues, correlating with poor prognosis. In vitro, CCL@Bmi1 siRNA significantly enhanced cisplatin sensitivity in resistant SK-OV-3/DDP cells. In vivo studies using xenograft and primary ovarian cancer mouse models demonstrated marked tumor growth suppression following treatment with CCL@Bmi1 siRNA, without notable systemic toxicity. Immunohistochemical analyses showed reduced expression of CSC-associated and multidrug resistance markers in tumor tissues. These findings suggest that Bmi1-targeted codelivery nanotherapeutics represent a promising strategy to counteract chemoresistance and improve therapeutic outcomes inOC.  \nKeywords Co-delivery system, Cisplatin resistant, Ovarian cancer, Cancer stem cells  \nOvarian cancer (OC) continues to be one of the most fatal gynecological malignancies, largely attributable to its high recurrence rate and the development of intrinsic or acquired chemoresistance1–3. While cisplatin is a fundamental component of first-line chemotherapy and initially elicits positive responses, the majority of patients eventually experience relapse due to the emergence of resistance4,5. A growing body of evidence suggests that cancer stem cells (CSCs) are pivotal in facilitating chemoresistance and tumor recurrence6. These CSCs are characterized by their abilities for self-renewal, pluripotency, and pronounced tumorigenicity, which allow them to withstand conventional chemotherapy7. In the context of OC, the persistence of ovarian cancer stem cells (OCSCs) exacerbates disease progression and is associated with poor clinical outcomes8.  \nA substantial body of research has indicated that chemoresistance in OC is predominantly facilitated by the persistence of OCSCs, which play a critical role in tumor initiation, metastasis, and recurrence9. These OCSCs are distinguished by their capacity to remain quiescent, withstand cytotoxic damage, and re-enter the cell cycle in response to external stimuli, thereby contributing to an inherent resistance to cisplatin and other chemotherapeutic agents. Consequently, targeting the principal regulatory mechanisms of OCSCs emerges asa promising approach to overcoming intrinsic cisplatin resistance. Among these regulatory factors, Bmi1 (BMo-MLV insertion region 1) has been identified as a critical oncogene that encodes a transcriptional repressor belonging to the polycomb group family. Functionally, Bmi1 inhibits the Ink4a/Arf locus, a key tumor suppressor region that regulates cell proliferation, differentiation, and apoptosis, thereby facilitating the self-renewal and survival of CSCs10.  \nThe overexpression of Bmi1 has been documented in various malignancies, including colorectal, gastric, breast, prostate, and non-small cell lung cancers, and is strongly associated with tumor aggressiveness and poor prognosis11, 12. In the context of OC, Bmi1 upregulation is linked to increased sphere-forming capacity, enhanced metastatic potential, and resistance to platinum-based chemotherapy13. Mechanistically, Bmi1 contributes to chemoresistance through seve","cbCaikjZxOZ8pg1E","https://ap.wps.com/l/cbCaikjZxOZ8pg1E","pdf",3428424,15,"English","# Introduction\n## Ovarian cancer chemoresistance and cancer stem cells\n## Bmi1 as a regulatory target\n# Methods and Experimental Design\n## Co-delivery nanocapsule engineering\n## Bioinformatics and cellular studies\n## In vivo xenograft and primary models\n## Immunohistochemical marker assessment\n# Results\n## Upregulation of Bmi1 and prognostic relevance\n## Enhanced cisplatin sensitivity in resistant cells\n## Tumor growth suppression without systemic toxicity\n## Reduced CSC and drug-resistance markers\n# Discussion\n## Targeted codelivery strategy for overcoming chemoresistance\n## Limitations of existing therapies and rationale","[{\"question\":\"Why is cisplatin resistance a major issue in ovarian cancer?\",\"answer\":\"Most patients initially respond to cisplatin but later relapse as resistance develops. This resistance is closely linked to persistent cancer stem cells that survive conventional chemotherapy.\"},{\"question\":\"What role does Bmi1 play in cancer stem cell–mediated chemoresistance?\",\"answer\":\"Bmi1 supports cancer stem cell self-renewal and survival by regulating pathways such as the Ink4a/Arf locus and other mechanisms affecting apoptosis and DNA repair. Its overexpression correlates with aggressive behavior and poor prognosis.\"},{\"question\":\"How does the CCL@Bmi1 siRNA nanocapsule system work in the study?\",\"answer\":\"The authors engineered a lipid-coated calcium carbonate nanocapsule system to co-deliver cisplatin and Bmi1 siRNA. This approach increases cisplatin sensitivity in resistant ovarian cancer cells and suppresses tumor growth in mouse models while reducing CSC-associated and multidrug-resistance markers.\"}]","Co-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomes chemoresistance in ovarian cancer | PDF",1790138826,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/420ef235f5175852dffce0e25d32d52c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eac265d4bb91b8d07ee188ad1a3d5fa2.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55f5a5a55ed955836390110ff9a00ba2.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0845cd96b5cbb5847e61b975641e9faa.webp",980,1287]